--- canonical_name: "Pentadecanoic Acid (C15:0)" alternate_names: "C15:0, Pentadecylic Acid, Pentadecanoate, FA15, Fatty15" canonical_topic: "Pentadecanoic Acid (C15:0) for Health & Longevity" short_topic_lc: pentadecanoic_acid_c150 creation_date: 2026-0914-1608 creator_ai_fullname: Opus 5 ep_keywords: "Odd-Chain Fatty Acids, Saturated Fatty Acids, Fatty Acids" --- # Pentadecanoic Acid (C15:0) for Health & Longevity
Evidence Review created on 09/14/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** C15:0, Pentadecylic Acid, Pentadecanoate, FA15, Fatty15 ## Motivation Pentadecanoic acid is a saturated fat with a 15-carbon backbone, an odd number that makes it unusual among dietary fats. It reaches the body almost entirely through dairy fat and the meat of grazing animals, where it makes up roughly one part in a hundred of the fat. For most of the last century it was studied only as a marker of how much dairy fat a person ate. That changed when large population studies repeatedly found that people carrying more of it in their blood developed diabetes and heart disease less often, even though it is a saturated fat and saturated fat has long been advised against. A company founded by the researcher who first pursued that observation now sells it as a capsule, and argues that decades of low-fat eating have left many people short of it. Others question whether the body needs it at all. This review examines where pentadecanoic acid comes from, how it behaves inside cells, what the human studies have and have not shown, what is known about its safety, and how it is being used. It sets out the evidence on each point and the limits of that evidence. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews of pentadecanoic acid from independent reviewers, a prioritized health-science platform, and a consumer watchdog. * [Q&A #64: Peptide Therapies—BPC-157, TB-500, & GHK-Cu](https://www.foundmyfitness.com/episodes/qa-64-dr-rhonda-patrick) - Rhonda Patrick A nine-minute segment starting at 24:43 weighs the two supplementation trials against the observational data. The episode itself is members-only; the public page lists the timestamp and the sources discussed. * [New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review](https://pubmed.ncbi.nlm.nih.gov/39395658/) - Ciesielski et al., 2024 An independent French academic group lays out the case for and against classifying this fatty acid as essential, and names the evidence that would be needed to settle it. * [A review of odd-chain fatty acid metabolism and the role of pentadecanoic Acid (c15:0) and heptadecanoic Acid (c17:0) in health and disease](https://pubmed.ncbi.nlm.nih.gov/25647578/) - Jenkins et al., 2015 The reference account of how odd-chain fats are absorbed, elongated and burned, written before any commercial interest existed; still the clearest source on their biochemistry. * [Is Fatty15 worth the hype?](https://www.cspi.org/article/fatty15-worth-hype) - Caitlin Dow A point-by-point audit of the marketing claims against the two published trials, from a subscription-funded consumer group that takes no industry money and so earns nothing from its verdict. * [Pentadecanoic acid (C15:0) and cardiovascular disease: A narrative review](https://pubmed.ncbi.nlm.nih.gov/41480001/) - Mercola, 2025 Gathers the cardiovascular observational and mechanistic literature in one place; reads as advocacy rather than appraisal, and predates the genetic analysis that found no causal effect. Note on the prioritized platforms: only FoundMyFitness has covered pentadecanoic acid in readable depth, and only inside a broader question-and-answer episode. A search of peterattiamd.com returns a single July 2024 newsletter whose summary line names the compound's potential to slow aging, but the published article carries no section on it, so there is nothing to read. Direct searches of hubermanlab.com, chriskresser.com, lifeextension.com and lifespan.io on 14 September 2026 returned no article, episode or newsletter on this compound — the topic is recent and narrow enough that most of them have not yet addressed it. ## Grokipedia * [Pentadecylic acid](https://grokipedia.com/page/Pentadecylic_acid) Covers physical properties, natural occurrence, biosynthesis and metabolism, biological role and the current research, with citations throughout — a neutral chemical and biological orientation before the clinical literature. ## Examine No Examine article on pentadecanoic acid exists. Searches of examine.com for both "pentadecanoic acid" and "C15:0" on 14 September 2026 returned no results; the compound is not in the site's supplement database. ## ConsumerLab * [What is C15:0 fatty acid (found in fatty15), and does it have health benefits?](https://www.consumerlab.com/answers/what-is-pentadecanoic-acid-and-does-it-have-health-benefits/pentadecanoic-acid/) Reviews the marketed claims, dosing, food equivalents and cost. ConsumerLab sells memberships, so most of the analysis sits behind a paywall; the free portion states that no clinical studies support the promoted uses. ## Systematic Reviews Every systematic review and meta-analysis of pentadecanoic acid pools observational studies of blood concentrations rather than trials of supplementation, and the list below covers both the claimed cardiometabolic benefit and the saturated-fat burden that raising intake carries. * [Biomarkers of dairy fat intake, incident cardiovascular disease, and all-cause mortality: A cohort study, systematic review, and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/34547017/) - Trieu et al., 2021 Eighteen observational studies pooled: higher blood pentadecanoic acid tracked with less cardiovascular disease, but not with lower death from any cause. * [Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies](https://pubmed.ncbi.nlm.nih.gov/30303968/) - Imamura et al., 2018 Sixteen cohorts and 63,682 participants analyzed to a single shared protocol: the largest and most rigorous estimate of the inverse diabetes association. * [Circulating Saturated Fatty Acids and Incident Type 2 Diabetes: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/31052447/) - Huang et al., 2019 Separates odd-chain from even-chain saturated fats and finds them moving in opposite directions for diabetes risk — the observation that opened the field. * [Saturated fatty acid biomarkers and risk of cardiometabolic diseases: A meta-analysis of prospective studies](https://pubmed.ncbi.nlm.nih.gov/36046138/) - Li et al., 2022 Forty-nine studies: odd-chain saturated fats track with less disease while total saturated fat tracks with more — the trade-off in raising dairy-fat intake. * [Biomarkers of dairy fat intake and risk of cardiovascular disease: A systematic review and meta analysis of prospective studies](https://pubmed.ncbi.nlm.nih.gov/28001085/) - Liang et al., 2018 The dissenting pooled estimate: no link between pentadecanoic acid and coronary disease or stroke, and a signal only for heart failure. No systematic review or meta-analysis of adverse effects from pentadecanoic acid supplementation exists; that side of the trade-off is unrepresented in the systematic-review literature and is covered below from the primary trials. ## Mechanism of Action Pentadecanoic acid is a 15-carbon saturated fat. The odd carbon number changes how it burns: breakdown yields propionyl-CoA (CoA is coenzyme A, the carrier that ferries fat fragments through metabolism), which enters the tricarboxylic acid cycle (the cell's main energy-producing loop) as succinyl-CoA and replenishes it — a route requiring vitamin B12 and biotin. It is also elongated to heptadecanoic acid and [desaturated into a family of odd-chain polyunsaturated fats](https://pubmed.ncbi.nlm.nih.gov/39617355/). Being saturated and straight-chained, it packs into membrane phospholipids and stiffens them. The leading hypothesis, advanced by the supplement's manufacturer, is that this makes membranes harder to oxidize and so less prone to [ferroptosis](https://pubmed.ncbi.nlm.nih.gov/39057678/) (an iron-dependent cell death driven by peroxidation of fragile fats). In [cell-based screens run by that same manufacturer](https://pubmed.ncbi.nlm.nih.gov/37960259/) it activates AMP-activated protein kinase (AMPK, the cell's energy sensor), inhibits the mechanistic target of rapamycin (mTOR, a growth and nutrient-sensing switch), binds peroxisome proliferator-activated receptors alpha and delta (PPAR-α and PPAR-δ, nuclear receptors that switch on fat burning), and damps Janus kinase signaling (JAK, an inflammatory relay). Its carnitine conjugate, pentadecanoylcarnitine, [fully activates cannabinoid receptors CB1 and CB2](https://pubmed.ncbi.nlm.nih.gov/35999445/). These actions appear at micromolar concentrations and are non-selective. Absorbed with dietary fat, it distributes into membrane phospholipids, red blood cells and fat tissue and clears slowly — plasma concentrations were [still rising after twelve weeks](https://pubmed.ncbi.nlm.nih.gov/39069269/) of daily dosing. A competing reading holds none of this is causal: blood concentrations mainly index dairy fat intake, and [genetic analysis finds no effect](https://pubmed.ncbi.nlm.nih.gov/41743064/) of lifelong higher concentrations on blood pressure. ## Historical Context & Evolution Pentadecanoic acid entered nutrition science as a measuring stick, not a treatment. Because humans were thought unable to make meaningful amounts of it, analysts from the 1970s onward used its concentration in blood and fat tissue as an objective record of dairy fat intake, [a role it still plays](https://pubmed.ncbi.nlm.nih.gov/25647578/). Attention shifted in 2014, when the EPIC-InterAct study reported that individual saturated fats behaved differently from one another: [even-chain ones tracked with more type 2 diabetes, odd-chain ones with less](https://pubmed.ncbi.nlm.nih.gov/25107467/). [Later pooled analyses](https://pubmed.ncbi.nlm.nih.gov/30303968/) confirmed the split. The supplement route came out of marine mammal medicine. Studying bottlenose dolphins under United States Navy care, Stephanie Venn-Watson found that animals with higher blood pentadecanoic acid had healthier metabolic profiles, and her [2020 paper proposed it as a candidate essential fatty acid](https://pubmed.ncbi.nlm.nih.gov/32424181/). She co-founded Seraphina Therapeutics, which sells it as fatty15, and the company's later papers describe a ["Cellular Fragility Syndrome"](https://pubmed.ncbi.nlm.nih.gov/39057678/) of deficiency caused by decades of saturated-fat avoidance. That framing is contested rather than settled. An independent academic group calls essentiality [an open question whose criteria are not yet met](https://pubmed.ncbi.nlm.nih.gov/39395658/); the National Academies of Sciences, Engineering, and Medicine has never classified it as essential; and a 2026 genetic analysis of two large United States cohorts reproduced the blood-pressure associations while [finding no sign of causation](https://pubmed.ncbi.nlm.nih.gov/41743064/). What changed across the decade was the direction of evidence on saturated fats generally — away from treating them as one uniform class — rather than agreement that this particular one must be supplemented. ## Expected Benefits ### High 🟩 🟩 🟩 No benefit reaches High: the human outcome and validated-surrogate findings for this compound come from observational cohorts and from two small randomized trials that measured different endpoints, so no clinical endpoint has been replicated across more than one trial. ### Medium 🟩 🟩 #### Lower Incidence of Type 2 Diabetes Blood pentadecanoic acid is consistently and inversely associated with developing type 2 diabetes. The proposed mechanism is better insulin signaling and less liver fat, but the association may instead reflect dairy fat intake or the wider eating pattern that supplies it. The evidence base is a [pooled analysis of 16 prospective cohorts](https://pubmed.ncbi.nlm.nih.gov/30303968/) covering 63,682 people and 15,180 new cases, analyzed to one shared protocol, supported by an [independent systematic review](https://pubmed.ncbi.nlm.nih.gov/31052447/). No trial has tested whether supplementing lowers incidence, and the association was stronger in women than in men. **Magnitude:** Hazard ratio (the relative rate of new cases between groups) 0.80, with a 95% confidence interval (the range in which the true value most likely lies) of 0.73–0.87, across the 10th-to-90th percentile range of blood pentadecanoic acid; the separate systematic review gives a relative risk (the same idea expressed as a ratio of risks) of 0.86, 0.76–0.98, per standard deviation (a unit of spread in the measurements). #### Lower LDL Cholesterol In the only randomized trial to test the supplement against an active comparator, adding 300 mg daily to a Mediterranean-style diet lowered LDL cholesterol (low-density lipoprotein, the cholesterol-carrying particles that drive artery plaque) further than the same diet alone in [88 Chinese women with fatty liver disease](https://pubmed.ncbi.nlm.nih.gov/38035997/). The mechanism is unclear; the supplemented arm also gained *Bifidobacterium adolescentis* in the gut. No other lipid measure separated the arms, weight and liver fat did not, and an edible-oils manufacturer part-funded the trial. **Magnitude:** LDL cholesterol fell further on 300 mg daily plus a Mediterranean-style diet than on that diet alone, in women with fatty liver disease over 12 weeks; the literature reports no outcome figure for this specific contrast in any publicly retrievable form, and no second trial has measured it. ### Low 🟩 #### Lower Cardiovascular Disease Risk ⚠️ Conflicted Pooled observational data point both ways. The [largest meta-analysis, 18 studies](https://pubmed.ncbi.nlm.nih.gov/34547017/), found less total cardiovascular disease at higher blood concentrations; an [earlier 13-study meta-analysis](https://pubmed.ncbi.nlm.nih.gov/28001085/) found nothing for coronary disease or stroke; and [two large cohorts](https://pubmed.ncbi.nlm.nih.gov/41743064/) found no link to new cardiovascular events. Net reading: a small association, probably not causal. **Magnitude:** Relative risk 0.88 (0.78–0.99) for total cardiovascular disease, highest versus lowest tertile (the top third of the group compared with the bottom third, ranked by blood concentration), in the 18-study meta-analysis; the earlier 13-study meta-analysis gave 0.94 (0.77–1.15), with only heart failure reaching statistical significance (a result unlikely to be chance alone) there at 0.72 (0.55–0.95). #### Lower Blood Pressure and Less Incident Hypertension ⚠️ Conflicted Two large United States cohorts [found modestly lower systolic and diastolic pressure and fewer new hypertension diagnoses](https://pubmed.ncbi.nlm.nih.gov/41743064/) at higher blood concentrations, replicated across both, and a [national nutrition survey found the same pattern](https://pubmed.ncbi.nlm.nih.gov/40542410/). The genetic analysis in the cohort study found no causal effect. Net reading: association without demonstrated cause. **Magnitude:** Systolic pressure 1.47 mmHg lower per standard deviation of blood pentadecanoic acid (95% confidence interval 0.96–1.99 lower), diastolic 1.13 mmHg lower, and hazard ratio 0.86 (0.78–0.95) for hypertension over ten years; the national survey gives an odds ratio (the ratio of the odds of having the condition between groups) of 0.78 (0.66–0.93). #### Improved Liver Enzymes In the only placebo-controlled trial, the [half of the treated group whose blood concentration passed 5 µg/mL](https://pubmed.ncbi.nlm.nih.gov/39069269/) had larger falls in liver enzymes than those who did not. This comparison sat inside the treatment arm of 30 young adults with excess weight, not against placebo, so it is hypothesis-generating. **Magnitude:** Alanine aminotransferase (a liver enzyme released when liver cells are stressed) fell 29 U/L further, and aspartate aminotransferase (a related enzyme found in liver and muscle) 6 U/L further, in responders than in non-responders over 12 weeks. #### Higher Hemoglobin The same responder subgroup showed a larger rise in hemoglobin, consistent with animal work in which pentadecanoic acid [corrected anemia](https://pubmed.ncbi.nlm.nih.gov/32424181/). It rests on the same within-arm comparison in [30 participants](https://pubmed.ncbi.nlm.nih.gov/39069269/), and the supplement and placebo groups did not differ overall. **Magnitude:** Hemoglobin rose 0.60 g/dL further in responders than in non-responders over 12 weeks in the 30-participant trial. ### Speculative 🟨 #### Longevity-Pathway Activity Comparable to Rapamycin Across twelve human cell systems it produced 36 clinically relevant activities, sharing 24 with [rapamycin](https://pubmed.ncbi.nlm.nih.gov/37960259/). The basis is cell-based screening by the manufacturer only; no human outcome data exist. #### Selective Anticancer Activity At blood-level concentrations it [suppressed growth of selected lymphoma and breast-cancer cell lines](https://pubmed.ncbi.nlm.nih.gov/41097159/), and dietary intake slowed [bladder-tumor development in mice](https://pubmed.ncbi.nlm.nih.gov/41339867/). The basis is laboratory and animal work alone, with no human trials. #### Cognitive-Health Support A [manufacturer study](https://pubmed.ncbi.nlm.nih.gov/40332352/) reports that it blocks two brain enzymes governing mood and memory signals, and documents Alzheimer-like deposits in aged dolphins. The basis is enzyme assays and animal tissue; no human cognitive data exist. ## Benefit-Modifying Factors * **Baseline blood concentration:** Only the trial participants who [pushed past 5 µg/mL](https://pubmed.ncbi.nlm.nih.gov/39069269/) showed biochemical change. Someone already eating full-fat dairy daily may sit near the proposed target and have little headroom; the measurement, not the diet history, decides this. * **Sex:** The [pooled diabetes analysis](https://pubmed.ncbi.nlm.nih.gov/30303968/) found the inverse association clearly stronger in women than men, and the only active-comparator trial enrolled women exclusively. Whether men gain the same from supplementation has not been tested. * **Age:** In the [national survey](https://pubmed.ncbi.nlm.nih.gov/40542410/) the hypertension association held across the whole sample, but among those already above the upper concentration band it persisted only past age 65. No trial has yet enrolled older adults; the first one is scheduled for 2027. * **Pre-existing conditions:** Both trials recruited people with excess weight or fatty liver disease. The liver-enzyme and lipid signals therefore come from populations with something to correct, and may not transfer to metabolically healthy people. * **Habitual dietary fat:** Absorption follows dietary fat. People on very low-fat diets absorb less from a capsule and start from lower baseline concentrations, so the same dose produces a different exposure than it does on a higher-fat diet. * **Genetic variation in fat handling:** Variants in FADS1 and FADS2 (genes for the enzymes that add double bonds to fatty acids) alter how much is converted into the newly described odd-chain polyunsaturated fats, and so may shift which downstream effects appear. * **Vitamin B12 status:** Clearance of odd-chain fats runs through a vitamin B12-dependent enzyme. Low B12 status slows that step, which may blunt the metabolic effects that depend on the fat being burned rather than stored. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches High: no adverse outcome has been documented in more than one randomized trial, because both published trials report no treatment-related adverse events, so the class of evidence that a High grade requires — a replicated human adverse-event finding — does not exist. ### Medium 🟥 🟥 #### Cost Without Demonstrated Clinical Benefit The measurable risk is financial. Across [30 young adults with excess weight](https://pubmed.ncbi.nlm.nih.gov/39069269/) and [88 women with fatty liver disease](https://pubmed.ncbi.nlm.nih.gov/38035997/), supplementation changed no measure of body weight, waist circumference, total cholesterol, blood sugar or inflammation relative to its comparator. The exception was LDL cholesterol in the second trial. Its observational case is the kind [genetic analysis has since failed to support](https://pubmed.ncbi.nlm.nih.gov/41743064/). For a reader allocating a supplement budget, the recurring cost buys benefits that remain unreplicated, and is not spent on cardiometabolic measures that do rest on outcome trials. **Magnitude:** Roughly $50 for a 30-day supply at the label dose of 100 mg daily — about $600 a year — plus $199 for the manufacturer's blood test; matching the 200 mg and 300 mg daily doses actually used in the trials doubles or triples that outlay. #### Loss of Pentadecanoic Acid as an Interpretable Biomarker Supplementation reliably raises the blood concentration, which is exactly what makes the measurement uninformative afterwards. The entire observational literature, including the [18-study cardiovascular meta-analysis](https://pubmed.ncbi.nlm.nih.gov/34547017/), treats this fatty acid as a proxy for dairy fat intake. Once a capsule supplies it, a laboratory value can no longer be read as evidence of a dietary pattern, and any clinician interpreting an odd-chain fatty acid panel without knowing about the supplement will misread it. **Magnitude:** Blood pentadecanoic acid rose 1.88 µg/mL more than placebo over 12 weeks (P = 0.003; P is the probability that a difference this large would arise by chance alone), moving half the treated group above 5 µg/mL and out of the range the observational literature was built on. ### Low 🟥 #### No Safety Data Beyond Twelve Weeks or Above 300 mg Daily Every human safety observation comes from two [12-week](https://pubmed.ncbi.nlm.nih.gov/39069269/) [trials](https://pubmed.ncbi.nlm.nih.gov/38035997/) totalling 118 participants, none older than 45. Both report no significant adverse events, which is reassuring about common short-term effects and silent about uncommon or delayed ones, and about the indefinite daily use the product is sold for. **Magnitude:** Not quantified in available studies. No trial has run long enough or enrolled enough people to estimate the rate of any uncommon or delayed adverse effect, so the true rate of such effects is simply unknown. #### Added Saturated Fat on the Dairy Route Reaching a trial-sized dose from dairy brings 12–20 g of even-chain saturated fat and several hundred calories with it. Pooled biomarker data tie those even-chain fats to more cardiometabolic disease, in the same [49-study meta-analysis](https://pubmed.ncbi.nlm.nih.gov/36046138/) that finds odd-chain fats tracking the other way. The capsule route avoids this entirely. **Magnitude:** Relative risks for even-chain saturated fat biomarkers run 1.15 to 1.43 across cardiometabolic outcomes, and higher total saturated fat carries 1.50 (1.31–1.71) for cardiovascular disease, in that 49-study pooled analysis; no figure exists for the dairy route as practiced for this purpose. ### Speculative 🟨 #### Lipotoxicity (Cell Damage from Fat Overload) at Concentrations Above the Dietary Range High loads generated abnormal [endoplasmic reticulum sheets](https://pubmed.ncbi.nlm.nih.gov/40424131/) (the cell's membrane factory) and killed fission yeast, and muscle accumulation is [linked to muscle-cell death](https://pubmed.ncbi.nlm.nih.gov/33042406/). The basis is yeast and muscle-tissue laboratory work only. #### Impaired Glucose Handling in Pregnancy Supplementing pregnant mice produced [mild maternal glucose intolerance](https://pubmed.ncbi.nlm.nih.gov/39434548/) while accelerating offspring growth. The basis is a single animal study; no human pregnancy data exist, and no trial has enrolled pregnant participants. ## Risk-Modifying Factors * **Propionate-pathway genetics:** Variants in PCCA, PCCB (genes for the enzyme that starts propionate breakdown) or MMUT (the B12-dependent enzyme finishing it) cause propionic and methylmalonic acidemia (inherited blocks in that pathway), where odd-chain fats are restricted, not supplemented. * **Baseline vitamin B12 and methylmalonic acid:** Because clearance passes through a B12-dependent step, untreated deficiency is the one measurable state in which extra odd-chain fat load is theoretically unwise. Methylmalonic acid is the more sensitive of the two markers. * **Sex:** No sex-specific safety data exist. The active-comparator trial enrolled only women and the placebo-controlled trial enrolled both sexes without reporting adverse events by sex, so no difference can be confirmed or excluded. * **Pre-existing conditions:** Fat malabsorption (cystic fibrosis, pancreatic insufficiency, bile-acid disorders) reduces uptake and shifts unabsorbed fat into the colon. Pregnancy and breastfeeding are untested in humans and carry the only animal warning signal. * **Age:** Nobody over 45 has taken this in a published trial. Older adults carry more concurrent medications, more subclinical liver and kidney impairment, and more anemia of other causes, none of which has been studied against this compound. ## Key Interactions & Contraindications * **Lipid-lowering drugs (atorvastatin, rosuvastatin, ezetimibe, bempedoic acid):** Caution; additive, not adverse. The only trial-supported effect is a further fall in LDL cholesterol, which compounds with these agents. A repeat lipid panel at 12 weeks resolves the direction without assuming a drug dose change. * **Fat-absorption blockers (orlistat, bile-acid sequestrants such as cholestyramine, colesevelam):** Caution. Both reduce absorption of any ingested fat, including this one, lowering effective exposure. Separating the doses by at least four hours preserves uptake. * **Over-the-counter products (mineral oil, activated charcoal, psyllium and other bulk fibers):** Caution, absorption-level. Each traps or binds dietary fat and lowers uptake of this fatty acid; separating intake by four hours preserves it. No analgesic or antacid interaction has been described. * **Vitamin B12 and biotin supplements:** No caution required; additive and desirable. Breakdown of odd-chain fats consumes both cofactors; adequate status supports clearance. No dose adjustment is needed, but correcting a documented B12 deficiency first is the sensible sequence. * **Cannabinoid products (cannabidiol, tetrahydrocannabinol) and sedatives:** Theoretical caution only. The carnitine metabolite activates cannabinoid receptors in cell assays; whether ordinary oral doses reach receptor-relevant concentrations in people is unknown, so no additive sedation has been observed or excluded. * **Omega-3 fatty acids (eicosapentaenoic acid, docosahexaenoic acid):** Caution, mechanism-level only. Both compete for the same membrane phospholipid positions and both have anti-inflammatory activity in cell systems. No human interaction study exists; neither displaces the other at ordinary supplemental doses. * **Dairy-fat intake and ruminant meat:** Monitor total intake; additive by definition. Roughly 25–35 g of butter or 600 mL of whole milk supplies a trial-sized dose, so heavy dairy consumers reach higher total exposure plus 12–20 g of even-chain saturated fat. **Populations who should avoid Pentadecanoic Acid (C15:0):** * People with propionic acidemia or methylmalonic acidemia (inherited defects of propionate breakdown), for whom odd-chain fats are a substrate load that dietary management specifically restricts. * People with untreated vitamin B12 deficiency (serum B12 below 200 pg/mL or methylmalonic acid above 400 nmol/L) until the deficiency is corrected. * Pregnant and breastfeeding women, on the basis of a mouse study showing maternal glucose intolerance and the complete absence of human pregnancy data. * Children and adolescents under 18, who have never been enrolled in a trial of this compound at any dose. ## Risk Mitigation Strategies * **Measurement before and after:** A blood pentadecanoic acid level at baseline and again at 12 weeks separates responders from non-responders, the distinction that carried every biochemical change in the placebo-controlled trial, and prevents open-ended spending on a non-response. * **Disclosure on every lab requisition:** Recording it prevents a clinician reading a raised odd-chain fatty acid result as evidence of dairy intake or of low cardiometabolic risk, which is the concrete harm of losing the biomarker. * **A pre-set stop date at 12 weeks:** Both trials ran 12 weeks. Deciding in advance to continue only if liver enzymes, lipids or blood count moved prevents indefinite spending against benefits that were never demonstrated at the label dose. * **Vitamin B12 status established first:** Serum B12 above 400 pg/mL, or methylmalonic acid below 250 nmol/L, avoids loading odd-chain fat onto a blocked clearance pathway and prevents misreading a flat 12-week result as non-response. * **The label 100 mg daily with a fat-containing meal:** Absorption tracks dietary fat, and the lowest studied exposure is the reasonable starting point, limiting both cost and any dose-dependent gastrointestinal intolerance before escalating. * **A cap on total saturated fat rather than an addition:** On the dairy route, substituting for other saturated fat rather than adding to it holds down the even-chain saturated fat and calorie load that route carries. ## Therapeutic Protocol * **Standard dose:** The commercial product supplies 100 mg of free pentadecanoic acid once daily as a capsule. This is the only regimen used by practitioners, and it is lower than either dose tested in a trial. * **Trial-matched dose:** Published trials used 200 mg daily in young adults with excess weight and 300 mg daily alongside a Mediterranean-style diet. Two or three capsules daily reproduce trial exposure at two or three times the cost. * **Competing approach — the food route:** Roughly 25–35 g of butter or ghee, or 600 mL of whole milk, supplies a trial-sized dose at negligible cost, with 12–20 g of even-chain saturated fat and several hundred extra calories attached. * **Who popularized each:** The capsule approach comes from Seraphina Therapeutics and its co-founder Stephanie Venn-Watson, which sells the product. The dairy-fat route is the position of the independent academic groups that treat the compound as a dietary marker. * **Best time of day:** With the largest fat-containing meal, because absorption follows dietary fat. No study has compared morning with evening dosing, and no circadian effect has been described. * **Half-life:** Long. Plasma concentrations were still climbing after 12 weeks of daily dosing and fall over weeks, not hours, so steady state is reached slowly and a missed day is inconsequential. * **Single versus split dosing:** A single daily dose. The slow turnover removes any pharmacokinetic reason to split, and both trials dosed once daily. * **Genetic considerations:** Variants in FADS1 and FADS2 alter conversion into odd-chain polyunsaturated fats. Published protocols exclude carriers of propionate-pathway defects (PCCA, PCCB, MMUT) at any dose. * **Sex differences:** Observational associations were stronger in women, and the active-comparator trial enrolled only women. No dose difference by sex has been established or tested. * **Age considerations:** No published trial has enrolled anyone over 45. Older adults have no dose guidance beyond the label, and the first trial in that group is not scheduled to start until January 2027. * **Baseline biomarkers:** A starting blood concentration below the proposed 0.4% of total fatty acids identifies the group with headroom. Those already above it have no described reason to expect further change. * **Pre-existing conditions:** Excess weight and fatty liver disease were the entry conditions in both trials. Fat malabsorption reduces uptake, and untreated vitamin B12 deficiency is corrected before starting in described protocols. ## Discontinuation & Cycling * **Intended duration:** Framed as ongoing nutrient repletion rather than a course of treatment, so the marketed model is indefinite daily use. No trial has run beyond 12 weeks, so indefinite use is an extrapolation. * **Withdrawal effects:** None reported. Neither trial described rebound or discontinuation symptoms, and no mechanism predicts any, since the compound is a structural fat rather than a receptor-dependent drug. * **Tapering:** Not applicable. Blood concentrations decline over weeks on their own as membrane and fat-tissue stores turn over, so abrupt stopping produces a gradual fall without intervention. * **Cycling:** Not studied and not mechanistically motivated. Nothing in the published data suggests tolerance develops, so the usual rationale for cycling — restoring a blunted response — does not apply here. * **Practical stopping point:** Twelve weeks matches trial duration and is long enough for a repeat blood concentration and a repeat liver and lipid panel to show whether anything moved. ## Sourcing and Quality * **Form matters:** The studied material is pure free pentadecanoic acid, sold as FA15 in fatty15. Laboratory-grade pentadecanoic acid sold as a chemical reagent is not manufactured to food standards and is not an equivalent substitute. * **Purity specification:** The relevant markers are a stated purity of 98% or higher and a certificate of analysis naming the batch. The compound is produced synthetically or by microbial fermentation, so residual solvents and starting materials are the relevant contaminants. * **Third-party testing:** A seal from an independent verifier — United States Pharmacopeia, NSF International or Informed Choice — or a batch certificate from a laboratory unconnected to the seller carries weight, since supplement labels are not pre-approved by regulators. * **Reputable suppliers:** Seraphina Therapeutics is the patent holder and sole supplier of the studied material. Compounding pharmacies do not stock it, and no generic equivalent with published purity data is currently marketed. * **Food sources as an alternative:** Butter, ghee, whole milk, full-fat yogurt, hard cheese and ruminant meat all supply it at roughly 1% of their fat. Grass-fed dairy is modestly richer but not categorically different. * **Storage:** A saturated fatty acid is chemically stable and does not oxidize the way fish oil does, so refrigeration is unnecessary; ordinary cool, dry storage away from light preserves the capsule. ## Practical Considerations * **Time to effect:** Blood concentrations climb across the full 12 weeks of the published trials and had not plateaued. Any biochemical change appeared only at the 12-week mark, so meaningful reassessment before three months is premature. * **Common pitfall — expecting the association to transfer:** The population findings describe people with naturally higher concentrations, usually from dairy. Genetic analysis found no causal effect, so treating those figures as the expected result of a capsule overstates what is known. * **Common pitfall — dosing below the studied range:** The label supplies 100 mg daily; the trials used 200 mg and 300 mg. Someone taking the label dose is taking a dose no study has evaluated for any outcome. * **Common pitfall — buying the deficiency test:** The manufacturer sells a $199 blood test against a [deficiency threshold its own publications defined](https://pubmed.ncbi.nlm.nih.gov/39057678/). The same fatty acid panel is available from independent laboratories at a fraction of that price. * **Regulatory status:** Sold in the United States as a dietary supplement, so it is not reviewed for efficacy before sale and the marketed claims are not evaluated by the Food and Drug Administration. It is not an approved treatment for any condition. * **Cost and payer incentives:** Around $50 monthly, entirely out of pocket. No insurer or national health system reimburses either this supplement or its dairy-fat alternative, so no institutional payer has any financial stake in which one people choose. ## Interaction with Foundational Habits * **Sleep:** Direct interaction claimed but unmeasured. The marketed "deeper sleep" claim rests on the carnitine metabolite activating cannabinoid and serotonin 5-HT1A receptors in cell assays. No human sleep study exists, and neither trial recorded sleep, so the direction in people is unknown. * **Nutrition:** Direct and two-way. Absorption follows dietary fat, so the capsule belongs with the largest fat-containing meal. Dairy fat is simultaneously the food source and a competing route; a low-fat diet both lowers baseline concentrations and reduces uptake from a capsule. * **Exercise:** No demonstrated interaction. Activation of the cell's energy sensor overlaps mechanistically with endurance adaptation, which raises a theoretical question about blunting or amplifying training response, but no trial has measured strength, endurance or muscle mass with this compound. * **Stress management:** Indirect and speculative. The cannabinoid and serotonin receptor activity of the carnitine metabolite is the only basis for any stress-axis claim; no human study has measured cortisol, mood or stress reactivity, so no practical timing or pairing advice follows. ## Monitoring Protocol & Defining Success Before starting, the informative baseline is a blood pentadecanoic acid measurement — without it there is no way to tell a responder from a non-responder, and that distinction carried every biochemical change in the placebo-controlled trial — together with a liver panel, a fasting lipid panel with apolipoprotein B, glycated hemoglobin and fasting insulin, a complete blood count, and vitamin B12. These cover the outcomes the literature attaches to this fatty acid plus the one metabolic pathway that could plausibly be strained by it. For ongoing monitoring, both trials ran 12 weeks, so a sensible cadence repeats the identical panel at 12 weeks, again at 6 months, then every 12 months. Success is defined narrowly here: the blood concentration rising into the proposed range, with no deterioration in liver enzymes, lipids or blood count. Nothing in the published evidence supports expecting more than that. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |---|---|---|---| | Pentadecanoic acid (C15:0), plasma or red cell | Above 0.4% of total fatty acids; the trial response threshold was above 5 µg/mL | Confirms absorption and identifies responders | No conventional reference range exists because it is not a standard clinical test; fasting not required; independent laboratories price the panel far below the manufacturer's $199 test | | Alanine aminotransferase (ALT) | 10–25 U/L | Liver-cell stress; the measure that moved in responders | Conventional upper limits run to 40–55 U/L, well above the functional target; strenuous exercise within 48 hours of the draw raises it | | Aspartate aminotransferase (AST) | 10–25 U/L | Pairs with ALT to separate liver from muscle sources | Conventional limits run to 40 U/L; rises after hard exercise or muscle injury, so it is interpretable only alongside ALT | | LDL cholesterol | Below 100 mg/dL, and below 70 mg/dL with established plaque | The one lipid measure a trial has moved | Conventional cut-off is 130 mg/dL; fasting is not required with modern assays; best read together with apolipoprotein B | | Apolipoprotein B | Below 80 mg/dL | Counts every plaque-forming particle, not just cholesterol carried | Conventional ranges extend to 130 mg/dL; fasting not required; worth pairing once with lipoprotein(a), which is genetically fixed | | Glycated hemoglobin (HbA1c) | 4.8–5.4% | Tracks the diabetes association that underpins the whole benefit case | HbA1c reflects average blood sugar over roughly three months; conventional cut-off is 5.7%; falsely low when red cells are short-lived | | Fasting insulin | 2–6 µIU/mL | Detects insulin resistance years before glucose rises | Requires a 10–12 hour fast; conventional ranges reach 25 µIU/mL; pair with fasting glucose to calculate HOMA-IR (a simple index of insulin resistance) | | Hemoglobin and red cell distribution width | Hemoglobin in the middle of the reference range; RDW below 13% | The red-cell claim, and the primary endpoint of the 2027 trial | Both come free with a standard complete blood count; no fasting needed; conventional RDW limits reach 14.5% | | High-sensitivity C-reactive protein | Below 1.0 mg/L | Tests the anti-inflammatory claim made from cell studies | A general marker of body-wide inflammation; conventional "low risk" is below 3.0 mg/L; a recent infection or injury inflates it, so a repeat after 2 weeks is informative | | Vitamin B12 and methylmalonic acid | B12 above 500 pg/mL; methylmalonic acid below 250 nmol/L | Odd-chain fats clear through a B12-dependent enzyme | Conventional B12 floor is 200 pg/mL, low enough to miss functional deficiency; methylmalonic acid is the more sensitive marker; fasting preferred | Qualitative markers worth tracking alongside the laboratory values: * Sleep quality and time to fall asleep, given the marketed but untested sleep claim * Daytime energy and perceived exercise recovery * Cognitive clarity and concentration during the working day * Skin and hair condition, the other claim with no supporting study * Digestive comfort in the first two weeks, when any tolerance issue would appear ## Emerging Research * **First trial with a longevity-adjacent endpoint:** [NCT07812792](https://clinicaltrials.gov/study/NCT07812792), a Phase 2 placebo-controlled study of 93 healthy older adults testing two doses against red cell distribution width and biological-aging measures, sponsored by ReCellience15 and due to start in January 2027. * **The completed supplementation pilot:** [NCT04947176](https://clinicaltrials.gov/study/NCT04947176), the 30-participant placebo-controlled trial in young adults with excess weight whose responder analysis supplies the liver-enzyme and hemoglobin claims, [published by Robinson et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39069269/). * **The completed diet trial:** [NCT05259475](https://clinicaltrials.gov/study/NCT05259475), the 90-participant Singaporean TANGO study of a Mediterranean-style Asian diet with or without the supplement, [published by Chooi et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38035997/) and part-funded by an edible-oils manufacturer. * **Causality testing could weaken the case:** [Steffen et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41743064/) reproduced the blood-pressure associations across two cohorts and found no causal signal by Mendelian randomization (a genetic method for testing whether an association is causal). Extending that method to diabetes and cardiovascular endpoints would be decisive. * **The essentiality question remains open:** [Ciesielski et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39395658/) argue that classification as essential needs deficiency-and-repletion evidence that does not yet exist, while the same group has [described a previously unknown family of odd-chain polyunsaturated fats](https://pubmed.ncbi.nlm.nih.gov/39617355/) formed from it. * **Gut bacteria as an alternative source:** [Wu et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39468026/) showed that specific gut bacteria synthesize pentadecanoic acid when fed the right prebiotic, raising the possibility that feeding the microbiome reaches the same endpoint without a capsule. * **Cancer biology could cut either way:** [Venn-Watson, 2025](https://pubmed.ncbi.nlm.nih.gov/41097159/) reports selective killing of lymphoma lines at blood-level concentrations, while [Hoshikawa et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40424131/) report membrane lipotoxicity at higher loads, so the same property may prove useful or harmful. ## Conclusion Pentadecanoic acid is a minor saturated fat that reaches people mainly through dairy and the meat of grazing animals, now also sold as a capsule. The case for it rests almost entirely on blood-level studies in large populations, which repeatedly link higher amounts to less diabetes and, less consistently, to less heart disease and lower blood pressure. Those studies cannot separate the fat from the diet that supplies it, and a genetic analysis built to do so found no sign that the fat itself is doing the work. The trial evidence is thin: two short studies in small groups, neither of which changed weight, waist size or blood sugar. One found a further drop in the cholesterol fraction that drives artery disease when the capsule was added to a Mediterranean-style diet; the other found that the treated people whose blood levels rose most also had the largest improvements in liver enzymes and red blood cell counts, a comparison made inside the treated group rather than against placebo. Safety looks unremarkable over three months, and nothing longer has been studied. Most of the supporting laboratory work comes from the company that sells the product, and the diet trial was part-funded by an edible-oils manufacturer, while the sharpest scrutiny comes from a subscription-funded consumer group with no product to sell, and the fullest review sits behind a membership paywall. For someone tracking their own markers, the honest summary is a well-tolerated, moderately expensive supplement whose benefits remain associations rather than demonstrated effects. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**